Short Communication Irreversible Ototoxicity Associated with Difluoromethylornithine
نویسندگان
چکیده
Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the ratelimiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials. Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m/d, and generally when the cumulative dose exceeds 250 g/m. In a recently completed Barrett’s esophagus chemoprevention trial, a participant developed a 15-dB decrease in hearing at frequencies of 250, 2,000, and 3,000 Hz in the right ear and a z20-dB decrease in hearing at 4,000 to 6,000 Hz in the left ear after taking 0.5 g/m/d DFMO for approximately 13 weeks (cumulative dose of 45 g/m). The threshold shifts persisted 7 months after DFMO was discontinued. There was no obvious impact on the participant’s clinical hearing, but these findings were consistent with irreversible hearing loss. This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk. (Cancer Epidemiol Biomarkers Prev 2004;13(7):1250–2)
منابع مشابه
Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
DFMO (alpha-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has be...
متن کاملOrnithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
The ornithine decarboxylase-1 (ODC1) polymorphism at position +316 affects binding by transcriptional activators and repressors and modulates the risk of metachronous colorectal adenomas, particularly in association with aspirin use. We investigated the effects of ODC1 after treatment with difluoromethylornithine (eflornithine)/sulindac or placebo. Two hundred twenty-eight colorectal adenoma pa...
متن کاملPolyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
Combination chemoprevention for cancer was proposed a quarter of a century ago, but has not been implemented in standard medical practice owing to limited efficacy and toxicity. Recent trials have targeted inflammation and polyamine biosynthesis, both of which are increased in carcinogenesis. Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of...
متن کاملJournal of Biological Chemistry M409856-revision Functional Consequences of Polyamine Synthesis Inhibition by DFMO: Cellular Mechanisms for DFMO-mediated Ototoxicity
متن کامل
Antitumor properties of (2R,5R)-6-heptyne-2,5-diamine, a new potent enzyme-activated irreversible inhibitor of ornithine decarboxylase, in rodents.
(2R,5R)-6-Heptyne-2,5-diamine hydrochloride (MDL 72175) is a new, potent, and selective inhibitor of mammalian ornithine decarboxylase. MDL 72175 given p.o. in drinking fluid reduced by 80% the growth of EMT6 sarcoma in mice and of HTC hepatoma in rats. It prolonged the survival of mice bearing L1210 or P388 leukemias and inhibited the development of Lewis lung carcinoma in mice at doses 10- to...
متن کامل